Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in: Pituitary 2/1999

01-06-1999

Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients

Authors: Paolo Marzullo, Valeria Marinò, Diego Ferone, Carolina Di Somma, Rosario Pivonello, Mariagiovanna Filippella, Gaetano Lombardi, Annamaria Colao

Published in: Pituitary | Issue 2/1999

Login to get access
Metadata
Title
Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients
Authors
Paolo Marzullo
Valeria Marinò
Diego Ferone
Carolina Di Somma
Rosario Pivonello
Mariagiovanna Filippella
Gaetano Lombardi
Annamaria Colao
Publication date
01-06-1999
Publisher
Kluwer Academic Publishers
Published in
Pituitary / Issue 2/1999
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1023/A:1009932521242

Other articles of this Issue 2/1999

Pituitary 2/1999 Go to the issue

OriginalPaper

Cost-effectiveness and accuracy of the tests used in the differential diagnosis of Cushing's syndrome.

OriginalPaper

Results of a European Multicentre Study with Sandostatin® LAR® in Acromegalic Patients

OriginalPaper

Estrogen Receptors in Prolactinomas: A Clinico-Pathological study

OriginalPaper

The Fifth International Pituitary Congress - June 1998

OriginalPaper

Estrogen Receptor Beta mRNA Expression in Normal and Adenomatous Pituitaries

OriginalPaper

Leptin after IGF-I Generation Test in a Patient with Hypopituitarism and Myotonic Dystrophy Disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits